Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.

Mammoth Biosciences

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

National Institutes of Health

aMoon Fund

Decheng Capital

Verily

Pacific 8 Ventures

Plum Alley Investments

Mayfield Fund

Brook Byers

Senator Investment Group

Foresite Capital

Greenspring Associates

Sixth Street Partners

Tachyon Ventures

Redmile Group

Bradley Horowitz

Don’t miss this tutorial session with Agilent Technologies and Mammoth Biosciences! Join us for an informative afternoon, our own Wesley Addison will be presenting.
See you there! #Innovation #Science #TechTalk #Biotech

Today at Keystone Symposia on Molecular & Cellular Biology's Precision Genome Engineering conference, Mammoth Biosciences co-founder & CTO Janice Chen will present an update on “Developing in vivo Therapeutics with Ultracompact CRISPR Systems”. The talk will highlight our fundamental innovation on #ultracompact #crispr  cargo and progress towards unlocking in vivo delivery of next-generation gene editors beyond the liver.

We're #hiring a new Vice President, Technical Operations in Brisbane, California. Apply today or share this post with your network.

We're #hiring a new Vice President, Translational Sciences in Brisbane, California. Apply today or share this post with your network.

We're #hiring a new Principal Project Manager I - Drug Development/Therapeutics in Brisbane, California. Apply today or share this post with your network.

Jenny is an amazing leader that if you qualify for the role, you should apply.

BIO:MAMMOTH

Mammoth Biosciences

Financials Not Available